Pharma RSS Digest - 2026-05-07
Overview
Two distinct catalysts shaped Thursday's pharma landscape: a landmark clinical enrollment completion and a strategically-timed acquisition. Bayer's move to acquire Perfuse Therapeutics reflects the broader pressure facing legacy ophthalmology franchises as major patent cliffs approach—Eylea's $8.04 billion in combined 2025 revenue becomes vulnerable starting mid-2027. Meanwhile, Alebund Pharmaceuticals crossed a meaningful regulatory milestone for AP301, a novel phosphate binder for hyperphosphatemia in dialysis-dependent CKD patients, positioning the asset for potential US submission based on a single global pivotal trial. The contrast between these stories—one signaling consolidation in mature therapeutic categories, the other representing potential innovation in underserved CKD-mineral bone disease—underscores divergent strategic priorities across the sector. Market participants will watch whether Bayer's acquisition premium signals accelerating valuations for mid-stage ophthalmology assets, and whether Alebund can translate Phase III enrollment completion into competitive positioning against entrenched phosphate binder therapies.
Key Developments
Bayer bets $2.45 billion on ophthalmology pipeline refresh with Perfuse acquisition. Bayer announced agreement to acquire Perfuse Therapeutics, a San Francisco-based biotech with R&D operations in Durham, North Carolina, for up to $2.45 billion including $300 million upfront and up to $2.15 billion in development, regulatory, and commercial milestones. Perfuse's lead asset PER-001 is a small molecule endothelin receptor antagonist delivered as an intravitreal bio-erodible implant currently in Phase II for open-angle glaucoma and diabetic retinopathy. Phase IIa data showed 37.5% of high-dose glaucoma patients achieving at least 7 dB vision improvement versus 0% control, while diabetic retinopathy patients demonstrated +0.9 dB contrast sensitivity improvement versus -2.1 dB worsening in controls. The deal requires Perfuse shareholder approval and antitrust clearance. What happens next: Monitor for shareholder vote timing, antitrust review progress, and whether specific milestone triggers become public—these details will signal Bayer's confidence in PER-001's path forward.
Alebund completes enrollment for global Phase III pivotal trial of AP301 phosphate binder. Alebund Pharmaceuticals announced completion of patient enrollment in RESPOND-2, a global Phase III pivotal trial of AP301 for hyperphosphatemia in chronic kidney disease patients on maintenance dialysis. The trial enrolled 282 patients (138 in the US, 144 in China), and the FDA agreed this single global study will serve as the pivotal trial supporting US registration of AP301. A prior China Phase III trial (RESPOND-1) with 474 participants demonstrated AP301 was non-inferior to sevelamer carbonate at Week 12. Hyperphosphatemia affects approximately 95% of dialysis-dependent CKD patients, yet only about 40% of Chinese dialysis patients achieve target serum phosphate levels, suggesting significant unmet need. What happens next: Watch for topline efficacy and safety data readout from RESPOND-2, which will determine whether AP301 can advance toward US regulatory submission with a competitive profile against existing phosphate binders.
Alebund Pharmaceuticals clinical trial update
Watchlist
- Eylea Q1 2026 US sales of $941 million represent a 10% year-over-year decline, suggesting accelerating erosion ahead of patent expirations that could reshape the ophthalmology competitive landscape. [link]
- Bayer's stated strategy of acquiring differentiated pipeline assets rather than building internally may signal additional deal activity in therapeutic categories facing exclusivity loss. [link]
- Phase IIa results for PER-001 require confirmation in larger Phase III trials before regulatory approval, introducing clinical development risk into the milestone-dependent portion of the deal structure.